Compounds > ethyl 5-methyl-4-imidazolecarboxylate
Page last updated: 2024-12-07

ethyl 5-methyl-4-imidazolecarboxylate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ethyl 5-methyl-4-imidazolecarboxylate: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID99200
CHEMBL ID1704767
SCHEMBL ID1186099
MeSH IDM0489853

Synonyms (68)

Synonym
5-methyl-3h-imidazole-4-carboxylic acid ethyl ester
BB 0260581
nsc195976
4-carboethoxy-5-methylimidazole
nsc-195976
51605-32-4
MLS000564960
smr000152201
ENAMINE_002110
ethyl 4-methyl-5-imidazolecarboxylate, 98%
HMS1399P20
ethyl 5-methyl-1h-imidazole-4-carboxylate
ethyl 4-methyl-5-imidazolecarboxylate
inchi=1/c7h10n2o2/c1-3-11-7(10)6-5(2)8-4-9-6/h4h,3h2,1-2h3,(h,8,9)
vldubdzwwnlzcu-uhfffaoysa-
ethyl 5-methyl-4-imidazolecarboxylate
AKOS001020253
ethyl 4-methyl-1h-imidazole-5-carboxylate;ethyl 5-methyl-1h-imidazole-4-carboxylate
A7607
NCGC00246141-01
HMS2461M16
ethyl-4-methyl-5-imidazolecarboxylate
ethyl 5-methylimidazole-4-carboxylate
unii-et2tr8p0qg
1h-imidazole-4-carboxylic acid, 5-methyl-, ethyl ester
1h-imidazole-5-carboxylic acid, 4-methyl-, ethyl ester
einecs 257-315-3
nsc 195976
emizco cpd
et2tr8p0qg ,
ethyl 4-methylimidazole-5-carboxylate
ethyl 4-methyl-1h-imidazole-5-carboxylate
STL200435
FT-0649101
FS-3259
AKOS015860168
BBL027807
SCHEMBL1186099
5-methyl-4-imidazolecarboxylic acid ethyl ester
4-methyl-5-carbethoxyimidazole
5-methyl-1h-imidazole-4-carboxylic acid ethyl ester
ethyl 5-methyl-4-1h-imidazolecarboxylate
ethyl 4-methyl-imidazole-5-carboxylate
5-methyl-1h-imidazole-4-carboxylic acid, ethyl ester
DTXSID5068655
ethyl5-methyl-1h-imidazole-4-carboxylate
5-ethoxycarbonyl-4-methylimidazole
imidazole-4(or 5)-carboxylic acid, 5(or 4)-methyl-, ethyl ester
ethyl 4-methyl-1h-imidazole-5-carboxylate #
4-carbethoxy-5-methylimidazole
5-methyl-4-ethoxycarbonylimidazole
CHEMBL1704767
BS-3853
AC-28877
4-methyl-1h-imidazole-5-carboxylic acid ethyl ester
J-521329
CS-W008738
mfcd00014487
4-ethoxycarbonyl-5-methyl-imidazole
mfcd00005199
SY022376
BCP06408
ethyl 4-methyl-5-imidazolcarboxylate
AMY11869
EN300-16894
5-methyl-1h-imidazole-4-carboxylicacidethylester
E1386
Z56813343
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency22.38720.035520.977089.1251AID504332
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's4 (57.14)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.20 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610